Gynecologic Oncology Group

妇科肿瘤组

• 批准号: 7931277
• 负责人: Philip J. DiSaia
• 金额: $ 14.33万
• 依托单位: GYNECOLOGIC ONCOLOGY GROUP
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-05-01 至 2012-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7931277
• 关键词: Address; Area; Basic Science; Biology; Carboplatin; Categories; Cervical; Cervix carcinoma; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collection; Combination Drug Therapy; Commit; Communities; Development; Developmental Therapeutics Program; Diagnostic; Discipline; Disease; Early Diagnosis; Early treatment; Education; Endometrial; Endometrial Carcinoma; Evaluation; Fostering; Future; Gynecologic; Gynecologic Oncology Group; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Medical Informatics; Modality; Nonprofit Organizations; Outcome; Ovarian Carcinoma; Paclitaxel; Patient Care; Patients; Phase; Phase II Clinical Trials; Platinum; Prevention program; Procedures; Process; Progress Reports; Public Health; Quality of Care; Quality of life; Quality-of-Life Assessment; Radiosurgery; Randomized Controlled Clinical Trials; Rare Diseases; Recurrence; Reporting; Research; Research Personnel; Risk; Series; Staging; System; Systemic Therapy; Techniques; Testing; Therapeutic; Translational Research; anticancer research; base; cancer prevention; chemotherapeutic agent; chemotherapy; cytotoxic; data management; design; high risk; high standard; improved; innovation; interdisciplinary collaboration; meetings; multidisciplinary; organizational structure; processing speed; programs

DESCRIPTION (provided by applicant): The Gynecologic Oncology Group is a non-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and basic research in the field of Gynecologic Malignancies. The Group is committed to maintaining the highest standards in clinical trials development, execution, analysis and distribution of results. Continuous evaluation of our processes is utilized in order to constantly improve the quality of patient care. The Gynecologic Oncology Group (GOG) is the foremost multidisciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1979, the GOG has been a recognized leader in the development of new forms of treatment and has relied on the Phase II trials as the design to identify new information. Supporting that major activity are the concerted efforts of: multidisciplinary committees; committees focused on special areas of expertise such as developmental therapeutics, quality of life, translational research, and cancer prevention and control; and modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new chemotherapeutic agents and innovative therapeutic approaches in gynecologic cancers; and this program has introduced important findings for study in the phase III setting. In patients with advanced cervical, endometrial and ovarian cancers, the GOG has defined significant improvement associated with the use of systemic therapy. The GOG has performed a series of trials which have defined: the standard use of paclitaxel plus carboplatin in ovarian carcinoma, concurrent platinum-based chemoradiation in stage IB-IVA carcinoma of the cervix, combination chemotherapy in advanced or recurrent carcinoma of the cervix, and chemotherapy in patients with advanced or high-risk limited endometrial carcinoma. In addition, the GOG has been active in developing new mechanisms to enhance translational research, cancer prevention and control and medical informatics. The Group has collaborated actively with the NCI in evaluating new data management collection and reporting systems. Future efforts will focus on: evolving a better understanding of the biology of gynecologic cancers, improving patient outcome through continued trials of both cytotoxic and biologically targeted agents in combination with surgery and radiation, and enhancing quality of life of patients with gynecologic cancers.

描述（由申请人提供）：妇科肿瘤学集团是一个非营利组织，目的是在妇科恶性肿瘤领域促进临床和基础研究的质量和完整性卓越。该小组致力于维持临床试验开发，执行，分析和结果分布的最高标准。为了不断提高患者护理质量，对我们的过程进行了持续评估。 妇科肿瘤学组（GOG）是致力于研究妇科恶性肿瘤研究的最重要的多学科合作临床试验研究小组。自1979年成立以来，GOG一直是新形式治疗形式的公认领导者，并依靠II期试验作为确定新信息的设计。支持这一主要活动的是：多学科委员会的一致努力；委员会专注于特殊领域，例如发育治疗，生活质量，转化研究以及预防和控制的委员会；和模式委员会在每个相关诊断和治疗学科中提供最新方法和程序。 GOG在研究新的化学治疗剂和妇科癌症的创新治疗方法方面具有积极的有效计划。该计划在第三阶段设置中介绍了重要的研究结果。在患有晚期宫颈，子宫内膜和卵巢癌的患者中，GOG定义了与全身治疗相关的显着改善。 GOG进行了一系列定义的试验：紫杉醇加上卡泊肽在卵巢癌中的标准用途，在子宫颈的IB-IVA阶段同时基于铂的化学放疗，晚期或高级糖尿病患者的高级或经常性癌症中的IB-IVA癌，结合化学疗法在高级或经常性癌症中，以及高晚期疗法疗法。此外，GOG一直积极开发新机制，以增强转化研究，预防癌症和控制和医学信息学。该小组已与NCI积极合作，以评估新的数据管理收集和报告系统。未来的努力将重点关注：对妇科癌症的生物学有更好的了解，通过继续试验的细胞毒性和生物学靶向剂与手术和放射线相结合，从而改善患者的结果，并提高妇科癌症患者的生活质量。